Neurodegeneration Conference 2012
|Chairs||Anthony Turner (University of Leeds)
Frederic Checler (Universite de Nice, France)
|Date||Tuesday November 27 2012 - Saturday December 1 2012|
|Advertising Opportunities||Please contact us to discuss advertising, exhibition & sponsorship opportunities at the Neurodegeneration conference.|
|Synopsis||This conference will focus on recent advances in neurodegenerative diseases, ranging from basic science to clinical and pharmaceutical developments, and will highlight current understanding of underlying mechanisms, new research directions, and therapeutic strategies. The conference will span Alzheimer's and other dementias twenty years since formulation of the amyloid cascade hypothesis, Parkinson's disease, prion diseases, as well as interactions and common mechanisms among neurodegenerative diseases. New concepts in any aspect of neurodegeneration/regeneration are, however, welcomed.
Featured will be plenary lectures from leading investigators, oral presentations from selected abstracts, and poster sessions covering each of the topics. Participation of younger scientists is particularly encouraged and there will be ample opportunity for informal discussions to develop new collaborations in an attractive environment on the Riviera Maya.
We are honoured to be able to offer the JBC/Herbert Tabor Award at this conference. The awardee is selected on the basis of their submitted abstracts by a committee composed of the conference organizers and a JBC associate editor. The winner will be given the opportunity to present their work in a short oral presentation at the meeting. Students, postdoctoral researchers, and faculty members who have not yet received tenure are eligible. The award includes a plaque and a $1,500 prize. For further information and previous winners, please click here
Register now and submit your abstract for consideration!
|Confirmed oral presentations||
Programme · Talk Titles
Sorry, but all abstract deadlines have passed.
To secure your place at the conference, register now.
|Register now () to secure your place.|
Multiple attendance discount: 3 or more members from the same lab are eligible for a discount. Please contact us.
Multiple conference discount: We can offer you a discount if you wish to attend multiple conferences. Please contact us.
Andrea LeBlanc (McGill University)
Caspase-6 activation in the hippocampus induces age-dependent memory impairment in mice and humans
Andrzej Szutowicz (Medical University of Gdansk, Department of Laboratory Medicine)
Shortages of acetyl-CoA ? an early event of cholinergic neuron degeneration and target for neuroprotection
Anne Rovelet-Lecrux (Inserm)
Involvement of novel genes in autosomal dominant early-onset Alzheimer disease and reassessment of the role of APOE
Cristine Alves da Costa (Universite Nice, France)
Evidence that parkin is more than a simple ubiquitin-ligase
Dale Schenk (Elan Pharmaceuticals)
David Allsop (Lancaster University, UK)
Development of peptide-inhibitor nanoparticles (PINPs) as inhibitors of beta-amyloid oligomer formation
Edward Parkin (Lancaster University)
The amyloid precursor protein and proteolysis; molecular overlaps in Alzheimer?s disease and cancer
Eliezer Masliah (University of California at San Diego)
Emmanuel Planel (Universite Laval)
Obesity, type 2, and type 1 diabetes: how do they affect tau pathology in the mouse brain?
Eric Karran (Alzheimer?s Research UK)
Developing drugs for Alzheimer?s disease: past, present and future.
Gemma Casadesus Smith (Case Western Reserve University)
Targeting Metabolic Hormone Dysregulation as a Treatment for AD
Guojun Bu (Mayo Clinic)
ApoE and apoE receptors in brain lipid metabolism, synaptic functions and clearance of amyloid-beta
Hans-Ulrich Demuth (Probiodrug AG)
GLUTAMINYL CYCLASE INHIBITORS ATTENUATING NEURODEGENERATION AND NEURINFLAMMATION IN MODELS OF ALZHEIMER‘S DIESEASE ARE AT CLINICAL STAGE
Hermona Soreq (The Hebrew University of Jerusalem)
MicroRNAs in the interface between inflammation and neurodegeneration
Huaxi Xu (Sanford Burnham)
Sorting Nexin 27 plays a Key Role in the Pathogenesis of Down Syndrome by Regulating Glutamate Receptor Recycling and Excitatory Synaptic Function.
Hugh Nuthall (Eli Lilly & Co. Ltd.)
Tau based models and approaches for the treatment of Neurodegenerative diseases
James Duce (University of Leeds)
A novel relationship between -amyloid protein precursor and tau in Alzheimer?s disease related iron disruption.
Jean-Charles Lambert (Universit? de Lille Nord de France)
Jean-Daniel Abraham (SysDiag UMR3145 CNRS/Bio-Rad)
Specific detection of N-truncated Abeta peptides in complex fluids
Jennifer Pocock (UCL Institute of Neurology)
p53 family pathway activation in microglia; implications for neurodegeneration
John Hardy (University College London)
Genetic analysis of neurodegeneration
John Mayer (University of Nottingham Medical School)
Regional neuronal depletion of 26S proteasomes mimics Parkinson’s disease and dementia with Lewy bodies
Karen Castillo (University of Chile)
Trehalose protects against amyotrophic lateral sclerosis progression by enhancing autophagy
Laura Morelli (Fundacion Instituto Leloir)
Human Insulin-degrading enzyme is a target of mitochondrial biogenesis pathway and modulates mitochondrial Aß accumulation.
Lawrence Rajendran (University of Zurich)
Cellular Complexity underlying b-amyloid production
Luigi Puglielli (University of Wisconsin - Dept of Medicine)
Inhibition of the ER-based acetyltransferases, ATase1 and ATase2, prevents Alzheimer’s disease in cellular and animal models of the disease.
Malcolm Leissring (Mayo Clinic)
Proteolytic degradation of the amyloid beta-protein: an historical perspective
Marcela Karpuj (Bioa2z)
A novel method for membrane protein regulation in cell culture.
Marco Prado (The University of Western Ontario )
The Prion Protein Partner, STI1, is involved in embryonic development, cellular stress and protects neurons against Abeta-induced cell death
MARCO RACCHI (Dept. of Drug Sciences - Pharmacology, University of Pavia)
ROLE OF p53 IN ALZHEIMER?S DISEASE PATHOGENESIS
Mark Cookson (Laboratory of Neurogenetics NIH)
Martine Barkats (Inserm U974-Institut de Myologie)
AAV gene transfer to the CNS: application to gene therapy of Spinal Muscular Atrophy
Michael Ugrumov (Russian Academy of Sciences)
Parkinson?s disease and hyperprolactinemia: new insight into pathogenesis, diagnostics and therapy
Minerva Carrasquillo (Mayo Clinic Jacksonville)
Brain Expression Genome-Wide Association Study (eGWAS) Identifies Human Disease-Associated Variants
Nabil Seidah (IRCM)
The secretory proprotein convertase PC7: an anxiety-modulating proteinase
Natalia Nalivaeva (University of Leeds)
Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease
Nathalie Pierrot (Universit? catholique de Louvain)
APP-mediated regulation of neuronal cholesterol turnover and synaptic activity: a new therapeutic target for the treatment of AD.
Nibaldo Inestrosa (Catholic University of Chile)
Regulation of the Neuronal Function by Wnts
Nicolas Sergeant (University of Lille)
IN VIVO THERAPEUTIC STRATEGIES AGAINST TAU PATHOLOGY: FROM EXERCISE TO IMMUNOTHERAPY
Nigel Hooper (University of Leeds)
Prion protein as a receptor for amyloid- oligomers ? implications for Alzheimer?s disease
Olga Corti (CRicm Inserm U975)
Novel molecular mechanisms uderlying the mitochondrial quality control functions of the PINK1/Parkin pathway
Patrick Kehoe (University of Bristol)
The Angiotensin hypothesis of AD - where have we go to, where to next?
Paul Fraser (University of Toronto)
ABCA7 Effect on Amyloid Processing and Relationship to Alzheimer Disease
Peter St George-Hyslop (Cambridge Institute for Medical Research)
Raphaelle Pardossi-Piquard (cnrs)
AICD: a key player in AD pathology?
Rene Vidal (University of Chile)
Targeting the UPR transcription factor XBP1 protects against Huntington?s disease in vivo.
Sangram Sisodia (Neuroscience at The University of Chicago)
PRESENILIN FUNCTION IN HEALTH AND DISEASE
Scott Miners (University of Bristol)
Enhancing amyloid β catabolism by intracerebral convection-enhanced delivery of neprilysin
Selina Wray (UCL Institute of Neurology)
Human stem cell models of frontotemporal dementia caused by a non-coding hexanucleotide repeat expansion in C9ORF72
Takaomi Saido (RIKEN Brain Science Institute)
A new mouse model of Alzheimer's disease: Distinguishing facts from artifacts
Thomas Boyer (University of Texas Health Science Center)
Mediator as a transducer of Amyloid Precursor Protein-dependent nuclear signaling
Tobias Hartmann (University of the Saarland)
AICD and A - regulator and target of neuronal lipid metabolism
Valentina Moskvina (University of Cardiff)
Vania Prado (Robarts Research Institute- UWO)
Consequences of cholinergic dysfunction in the cortex and hippocampus: highlights from VAChT-deficient mice
Vilma Martins (A C Camargo Hospital)
Prion protein-dependent neurotrophic signals are potentiated by astrocyte-released endosomal microvesicles carrying the co-chaperone STI1